Selected research
Industry Research
Etoricoxib Industry Research Report 2026
Market perspective
The global Etoricoxib market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Etoricoxib is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Etoricoxib is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Etoricoxib is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Etoricoxib include Shanghai Shyndec Pharmaceutical, Qilu Pharmaceutical, Merck & Co, Easton Biopharmaceuticals, Beijing Tide Pharmaceutical, Morepen Laboratories, Metrochem API, Hema Pharmaceuticals and Frosst Iberica SA, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Etoricoxib market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Etoricoxib Market by Company
Shanghai Shyndec Pharmaceutical
Qilu Pharmaceutical
Merck & Co
Easton Biopharmaceuticals
Beijing Tide Pharmaceutical
Morepen Laboratories
Metrochem API
Hema Pharmaceuticals
Frosst Iberica SA
Atom Pharma
Etoricoxib Segment by Type
120 mg
30 mg
60 mg
90 mg
Etoricoxib Segment by Application
Hospital
Pharmacy
Others
Etoricoxib Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Etoricoxib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Etoricoxib and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Etoricoxib.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Etoricoxib manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Etoricoxib by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Etoricoxib in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 120 mg
- 30 mg
- 60 mg
- 90 mg
Applications
- Hospital
- Pharmacy
- Others
Companies covered
- Shanghai Shyndec Pharmaceutical
- Qilu Pharmaceutical
- Merck & Co
- Easton Biopharmaceuticals
- Beijing Tide Pharmaceutical
- Morepen Laboratories
- Metrochem API
- Hema Pharmaceuticals
- Frosst Iberica SA
- Atom Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Etoricoxib Market Size (2021-2032)
- 2.2.2 Global Etoricoxib Sales (2021-2032)
- 2.2.3 Global Etoricoxib Market Average Price (2021-2032)
- 2.3 Etoricoxib by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 120 mg
- 2.3.3 30 mg
- 2.3.4 60 mg
- 2.3.5 90 mg
- 2.4 Etoricoxib by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Pharmacy
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Etoricoxib Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Etoricoxib Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Etoricoxib Revenue of Manufacturers (2021-2026)
- 3.4 Global Etoricoxib Average Price by Manufacturers (2021-2026)
- 3.5 Global Etoricoxib Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Etoricoxib, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Etoricoxib, Product Type & Application
- 3.8 Global Manufacturers of Etoricoxib, Established Date
- 3.9 Global Etoricoxib Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Shanghai Shyndec Pharmaceutical
- 4.1.1 Shanghai Shyndec Pharmaceutical Company Information
- 4.1.2 Shanghai Shyndec Pharmaceutical Business Overview
- 4.1.3 Shanghai Shyndec Pharmaceutical Etoricoxib Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Shanghai Shyndec Pharmaceutical Etoricoxib Product Portfolio
- 4.1.5 Shanghai Shyndec Pharmaceutical Recent Developments
- 4.2 Qilu Pharmaceutical
- 4.2.1 Qilu Pharmaceutical Company Information
- 4.2.2 Qilu Pharmaceutical Business Overview
- 4.2.3 Qilu Pharmaceutical Etoricoxib Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Qilu Pharmaceutical Etoricoxib Product Portfolio
- 4.2.5 Qilu Pharmaceutical Recent Developments
- 4.3 Merck & Co
- 4.3.1 Merck & Co Company Information
- 4.3.2 Merck & Co Business Overview
- 4.3.3 Merck & Co Etoricoxib Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck & Co Etoricoxib Product Portfolio
- 4.3.5 Merck & Co Recent Developments
- 4.4 Easton Biopharmaceuticals
- 4.4.1 Easton Biopharmaceuticals Company Information
- 4.4.2 Easton Biopharmaceuticals Business Overview
- 4.4.3 Easton Biopharmaceuticals Etoricoxib Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Easton Biopharmaceuticals Etoricoxib Product Portfolio
- 4.4.5 Easton Biopharmaceuticals Recent Developments
- 4.5 Beijing Tide Pharmaceutical
- 4.5.1 Beijing Tide Pharmaceutical Company Information
- 4.5.2 Beijing Tide Pharmaceutical Business Overview
- 4.5.3 Beijing Tide Pharmaceutical Etoricoxib Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Beijing Tide Pharmaceutical Etoricoxib Product Portfolio
- 4.5.5 Beijing Tide Pharmaceutical Recent Developments
- 4.6 Morepen Laboratories
- 4.6.1 Morepen Laboratories Company Information
- 4.6.2 Morepen Laboratories Business Overview
- 4.6.3 Morepen Laboratories Etoricoxib Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Morepen Laboratories Etoricoxib Product Portfolio
- 4.6.5 Morepen Laboratories Recent Developments
- 4.7 Metrochem API
- 4.7.1 Metrochem API Company Information
- 4.7.2 Metrochem API Business Overview
- 4.7.3 Metrochem API Etoricoxib Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Metrochem API Etoricoxib Product Portfolio
- 4.7.5 Metrochem API Recent Developments
- 4.8 Hema Pharmaceuticals
- 4.8.1 Hema Pharmaceuticals Company Information
- 4.8.2 Hema Pharmaceuticals Business Overview
- 4.8.3 Hema Pharmaceuticals Etoricoxib Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Hema Pharmaceuticals Etoricoxib Product Portfolio
- 4.8.5 Hema Pharmaceuticals Recent Developments
- 4.9 Frosst Iberica SA
- 4.9.1 Frosst Iberica SA Company Information
- 4.9.2 Frosst Iberica SA Business Overview
- 4.9.3 Frosst Iberica SA Etoricoxib Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Frosst Iberica SA Etoricoxib Product Portfolio
- 4.9.5 Frosst Iberica SA Recent Developments
- 4.10 Atom Pharma
- 4.10.1 Atom Pharma Company Information
- 4.10.2 Atom Pharma Business Overview
- 4.10.3 Atom Pharma Etoricoxib Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Atom Pharma Etoricoxib Product Portfolio
- 4.10.5 Atom Pharma Recent Developments
5 Global Etoricoxib Market Scenario by Region
- 5.1 Global Etoricoxib Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Etoricoxib Sales by Region: 2021-2032
- 5.2.1 Global Etoricoxib Sales by Region: 2021-2026
- 5.2.2 Global Etoricoxib Sales by Region: 2027-2032
- 5.3 Global Etoricoxib Revenue by Region: 2021-2032
- 5.3.1 Global Etoricoxib Revenue by Region: 2021-2026
- 5.3.2 Global Etoricoxib Revenue by Region: 2027-2032
- 5.4 North America Etoricoxib Market Facts & Figures by Country
- 5.4.1 North America Etoricoxib Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Etoricoxib Sales by Country (2021-2032)
- 5.4.3 North America Etoricoxib Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Etoricoxib Market Facts & Figures by Country
- 5.5.1 Europe Etoricoxib Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Etoricoxib Sales by Country (2021-2032)
- 5.5.3 Europe Etoricoxib Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Etoricoxib Market Facts & Figures by Country
- 5.6.1 Asia Pacific Etoricoxib Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Etoricoxib Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Etoricoxib Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Etoricoxib Market Facts & Figures by Country
- 5.7.1 South America Etoricoxib Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Etoricoxib Sales by Country (2021-2032)
- 5.7.3 South America Etoricoxib Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Etoricoxib Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Etoricoxib Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Etoricoxib Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Etoricoxib Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Etoricoxib Sales by Type (2021-2032)
- 6.1.1 Global Etoricoxib Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Etoricoxib Sales Market Share by Type (2021-2032)
- 6.2 Global Etoricoxib Revenue by Type (2021-2032)
- 6.2.1 Global Etoricoxib Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Etoricoxib Revenue Market Share by Type (2021-2032)
- 6.3 Global Etoricoxib Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Etoricoxib Sales by Application (2021-2032)
- 7.1.1 Global Etoricoxib Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Etoricoxib Sales Market Share by Application (2021-2032)
- 7.2 Global Etoricoxib Revenue by Application (2021-2032)
- 7.2.1 Global Etoricoxib Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Etoricoxib Revenue Market Share by Application (2021-2032)
- 7.3 Global Etoricoxib Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Etoricoxib Value Chain Analysis
- 8.1.1 Etoricoxib Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Etoricoxib Production Mode & Process
- 8.2 Etoricoxib Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Etoricoxib Distributors
- 8.2.3 Etoricoxib Customers
9 Global Etoricoxib Analyzing Market Dynamics
- 9.1 Etoricoxib Industry Trends
- 9.2 Etoricoxib Industry Drivers
- 9.3 Etoricoxib Industry Opportunities and Challenges
- 9.4 Etoricoxib Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst